Role of Macrophage Migration Inhibitory Factor (MIF) in Heart Failure

NCT03232671 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2022-11-04

No results posted yet for this study

Summary

Evaluating the additional value of Macrophage Migration Inhibitory factor (MIF) in cardiovascular diseases when assessed in clinical routine.

Conditions

  • Heart Diseases

Interventions

DIAGNOSTIC_TEST

MIF ELISA

Blood sample

Sponsors & Collaborators

  • University Hospital, Essen

    lead OTHER

Principal Investigators

  • Peter Lüdike, M.D. · University Hospital of Essen, Department of Cardiology and Vascular medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2020-04-30
Completion
2020-09-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03232671 on ClinicalTrials.gov